Major advances in the treatment of aggressive breast cancer

Credit: Michal Jarmoluk - Pixabay

MAJOR advances are being made in Valencia in the treatment of one of the most aggressive types of breast cancer.

A study by the Incliva Health Research Institute of Valencia Hospital, in conjunction with the Jimenez Diaz Foundation Health Research Institute (IIS-FJD), shows for the first time that the lack of miR-33b is related to a poor prognosis in HER2 + patients, one of the most aggressive breast cancers with a low survival rate; which opens the door for the creation of new drugs against this subtype of cancer.
One of the main findings of the study is the demonstration that miR-33b (a single-stranded RNA capable of regulating the expression of other genes) acts as a miRNA, a tumour suppressor in HER2 + breast cancer, which could inhibit migration and tumour invasion, in part, by preventing epithelial-mesenchymal transition, a crucial process during the development of tumorigenesis and metastasis.
The study was funded by the PI18 / 01219 Project and the CIBERONC Center for Networked Biomedical Research in Oncology (CB16 / 12/00481) of the Health Research Fund, Ministry of Economy and Competitiveness.


Thank you for taking the time to read this news article “Major advances in the treatment of aggressive breast cancer”. For more UK daily news, Spanish daily news and Global news stories, visit the Euro Weekly News home page.

FacebookTwitterRedditWhatsAppTelegramLinkedInEmailCopy Link
Go Back
Written by

Jennifer Leighfield

Jennifer Leighfield, born in Salisbury, UK; resident in Malaga, Spain since 1989. Degree in Translation and Interpreting in Spanish, French and English from Malaga University (2005), specialising in Crime, Forensic Medicine and Genetics. Published translations include three books by Richard Handscombe. Worked with Euro Weekly News since November 2006. Well-travelled throughout Spain and the rest of the world, fan of Harry Potter and most things ‘geek’.

Comments


    Leave a comment

    Your email address will not be published.